Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in …

B Schütt, A Kaiser, MH Schultze-Mosgau… - Human …, 2016 - academic.oup.com
STUDY QUESTION Does administration of vilaprisan (VPR) to healthy women for 12 weeks
reduce menstrual bleeding? SUMMARY ANSWER In this 12-week proof-of-concept phase 1 …

Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in …

B Schütt, A Kaiser… - Human …, 2016 - pubmed.ncbi.nlm.nih.gov
Study question Does administration of vilaprisan (VPR) to healthy women for 12 weeks
reduce menstrual bleeding? Summary answer In this 12-week proof-of-concept phase 1 …

Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in …

B Schütt, A Kaiser, MH Schultze-Mosgau… - Human Reproduction …, 2016 - europepmc.org
Pharmacodynamics and safety of the novel selective progesterone receptor modulator
vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in healthy women …

Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial in …

B Schutt, A Kaiser, MH Schultze-Mosgau… - Human …, 2016 - hero.epa.gov
Does administration of vilaprisan (VPR) to healthy women for 12 weeks reduce menstrual
bleeding? In this 12-week proof-of-concept phase 1 trial, most women (30/33, 90%) who …

[PDF][PDF] Pharmacodynamics and safety of the novel selective progesterone receptor modulator vilaprisan: a double-blind, randomized, placebo-controlled phase 1 trial …

B Schutt, A Kaiser, MH Schultze-Mosgau… - Human …, 2016 - researchgate.net
Uterine fibroids (UFs) are benign, hormone-sensitive tumours that originate from smooth
muscle cells of the uterus, which often affect women of reproductive age. Symptoms may …